A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids for the Treatment of First-Line Acute Graft-Versus-Host Disease
Study of Effects of Itacitinib in Combination with Corticosteroids for of Graft-Versus-Host Disease (GVHD) in Pregnant Partner
Sponsor: Incyte Corporation
Enrolling: Male and Female Patients
IRB Number: AAAR3758
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: Itacitinib is an investigational drug that is being developed by Incyte Corporation for use in the treatment of acute graft-versus-host disease (GVHD). At this time, it is not known whether the study drug has an effect on sperm or eggs, whether they are secreted in the semen or whether they have an effect on a fetus. We would like to collect medical information about you, your pregnancy, and the outcome of your pregnancy so that we can make a record of whether the study drug does or does not appear to have any effect.
This study is closed
Ran Reshef, MD
Do You Qualify?
Did you become pregnant while your partner was taking part in a study of Itacitinib? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator